Background. Empiric therapy of pneumonia is currently based on the site of acquisition (community or hospital), but could be chosen, based on risk factors for multidrug-resistant (MDR) pathogens, independent of site of acquisition.
Thus, the site of pneumonia acquisition is not always a good method to define pneumonia etiology. Previously, we showed that the therapeutic strategy for HCAP can be improved by using an algorithm based on the presence of risk factors for MDR pathogens, and that with this approach, >90% of patients received appropriate therapy, with only a little more than half being treated with broad-spectrum antibiotic therapy [11, 18] . In this algorithm, patients with HCAP were classified into groups with low or high MDR pathogen risks, and the former group was treated with CAP therapy, while the latter was treated with a HAP therapy regimen.
These findings raised the possibility that all patients with pneumonia (CAP, HCAP, HAP, and VAP) could be treated with a similar algorithm based on risk factors for MDR pathogens, independent of the site of pneumonia acquisition (community or hospital). We conducted this prospective, multicenter cohort study to evaluate whether a single algorithm could be safely applied to pneumonia patients of all types, in an effort to simplify therapy and avoid overuse of broad-spectrum therapy, while preserving good patient outcomes.
METHODS
This prospective multicenter cohort study was conducted between November 2013 and April 2017 at 12 Japanese hospitals. Informed consent was obtained from eligible patients, and the study was approved by the Committee for Ethics and Clinical Investigation of each participating hospital. The study was registered with the Japan Medical Association Center for Clinical Trials (JMA-IIA00146).
Definitions of Each Type of Pneumonia and the Algorithm for Therapy
All patients were hospitalized, and had radiographically confirmed pneumonia and appropriate clinical findings (see Supplementary Data). Patients with an infiltrate other than pneumonia were excluded. CAP, HCAP, HAP, and VAP were defined according to the ATS/IDSA guidelines [1] . Clinical criteria for each type of pneumonia are listed in the Supplementary Data.
Patients with pneumonia were classified into 4 groups on the basis of severity of the illness and the presence of other risk factors for MDR pathogens ( Figure 1 ). Severe illness included need for mechanical ventilation or intensive care unit (ICU) admission. Risk factors for MDR pathogens were (1) antibiotic therapy in the past 180 days; (2) poor functional status (Barthel Index <50 or performance status ≥3); (3) hospitalization for >2 days in the past 90 days; (4) occurrence ≥5 days after admission to an acute hospital; (5) hemodialysis; and (6) immunosuppression (see Supplementary Data). Pneumonia patients with 0-1 MDR risks (groups 1 and 3) were treated with CAP therapy (a β-lactam in combination with a macrolide), whereas pneumonia patients with ≥2 MDR risks (groups 2 and 4) were treated with HAP therapy (2-or 3-drug regimen that included an antipseudomonal β-lactam in combination with a quinolone or aminoglycoside, plus either optional linezolid or vancomycin) (Figure 1 ).
Outcome Measures and Clinical Assessment
We compared the baseline characteristics, presence of MDR risk factors, causative microorganisms, antibiotic regimens, and outcomes for (1) CAP, HCAP, and HAP vs VAP patients; and (2) pneumonia patients with 0-1 MDR risks vs pneumonia patients with ≥2 MDR risks. Multivariate mortality analyses were conducted in both the patients with all cases of pneumonia and nonintubated patients excluding VAP. The CURB-65 (confusion, blood urea nitrogen [BUN], respiratory rate, blood pressure, age ≥65 years) and the Pneumonia Severity Index (PSI) scores were used to assess the severity of pneumonia [19, 20] . The activities of daily living were evaluated using the Barthel Index [21] and/or performance status (PS): European Cooperative Oncology Group (see Supplementary Data) [22] . Patients with Barthel Index <50 points or PS ≥3 were defined as having poor functional status. Inappropriate antibiotic regimen according to the algorithm was defined when an identified etiologic pathogen was resistant to the combination of antibiotics recommended in the algorithm. Inappropriate therapy was defined when an identified etiologic pathogen was resistant to the initial antibiotic regimen actually administered. Measured outcomes were 30-day mortality and initial treatment failure (see Supplementary Data). Patients were followed from the time of onset of pneumonia for 30 days or until the day of death.
Microbiologic Evaluation
Sputum (for polymerase chain reaction and culture), serum, urine, and 2 samples of blood were collected for microbiologic examination, and microimmunofluorescence was used to measure for immunoglobulin G and immunoglobulin M antibodies against Chlamydophila (see Supplementary Data) [23] [24] [25] . The antimicrobial susceptibility of isolated bacterial pathogens was assessed on the basis of the minimum inhibitory concentration [26] . Methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, Acinetobacter baumannii, Serratia marcescens, Stenotrophomonas maltophilia, and extended-spectrum β-lactamase or carbapenemase-producing organisms were defined as MDR pathogens based on the ATS/IDSA guidelines [1] . An etiologic diagnosis was made based on the criteria listed in the Supplementary Data.
Statistical Analysis
Data are expressed as the median and interquartile range and analyzed using SPSS version 19.0 (IBM Corporation) software. Univariate analysis was performed using the χ 2 or Fisher exact test for categorical variables and the Mann-Whitney U test for continuous variables. Univariate and multivariate logistic regression analyses were performed to evaluate risk factors for 30-day mortality (dependent variable). The independent variables were decided based on review of the literature and clinical relevance (see Supplementary Data). Variables that showed a significant impact (P < .1) in the univariate analysis were included in the forward likelihood ratio stepwise multivariate logistic regression model to determine if any of them were independently related to outcome. The Hosmer-Lemeshow goodness-of-fit test was performed to assess the overall fit of the model. All reported P values are 2-tailed, with a P value <.05 considered statistically significant.
RESULTS

Patient Characteristics
A total of 1128 patients with suspected pneumonia were enrolled, with 39 excluded (see Supplementary Data). The characteristics of the remaining 1089 patients, including 656 CAP, 238 HCAP, 140 HAP, and 55 VAP, are summarized in Tables 1 and 2 . Using the algorithm, the 1089 patients were classified into groups 1 (n = 721), 2 (n = 233), 3 (n = 31), and 4 (n = 104) ( Figure 1 and Figure 1 . Classification of pneumonia patients in the current study using the algorithm modified from Niederman and Brito [18] . The specific antibiotic regimens for pneumonia stratified by the number of multidrug-resistant pathogen risk factors are listed. Abbreviations: CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; HCAP, healthcare-associated pneumonia; ICU, intensive care unit; MDR, multidrug-resistant; PS, performance status; VAP, ventilator-associated pneumonia. Abbreviations: CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; HCAP, healthcare-associated pneumonia; VAP, ventilator-associated pneumonia. 
Etiology of Pneumonia
A microbiologic diagnosis was established in 63.5% (691/1089) of all patients, including 61.1% with CAP, 59.7% with HCAP, 70% with HAP, and 90.9% with VAP (Table 4) . Table 4 shows the frequency of the etiologic microorganisms in each patient group. Streptococcus pneumoniae was the most frequent pathogen in both HCAP and CAP patients. Enterobacteriaceae were the most frequent pathogen in both HAP and VAP patients. The frequency of MDR pathogens including MRSA (7.3%, 6.4%, 2.9%, and 0.6%), Enterobacteriaceae (36.4%, 23.6%, 9.2%, and 6.6%), and P. aeruginosa (31%, 10%, 7.6%, and 3.5%) was highest in the order of VAP, HAP, HCAP, and CAP. Patients with ≥2 MDR risk factors (groups 2 and 4), compared to those with 0-1 MDR risk factor (groups 1 and 3), had a higher frequency of MDR pathogens (25.8% vs 5.3%, P < .001), including S. aureus (10.7% vs 4.4%, P < .001), MRSA (5.3% vs 0.8%, P < .001), P. aeruginosa (13.4% vs 3.6%, P < .001), and Enterobacteriaceae (19.6% vs 6.9%, P < .001). Chlamydophila pneumoniae was equally frequent (2.4%) in both groups, while Mycoplasma pneumoniae (5.7% vs 2.4%, P = .016) and Legionella pneumophila (1.7% vs 0.3%, P = .04) were more common in the group with 0-1 MDR risk factor ( Table 2 ).
Severity and Prognosis
Patients with ≥2 MDR risk factors (groups 2 and 4) had hypotension, altered mental status, respiratory failure, and dehydration more often than pneumonia patients with 0-1 MDR risk factor (groups 1 and 3). The activities of daily living and the nutritional status (serum albumin) were significantly more impaired in those with ≥2 MDR risk factors than in those with 0-1 MDR risk factor. The 30-day mortality was higher in the order of VAP (18.2%), HAP (13.6%), HCAP (6.7%), and CAP (4.7%), but the mortality rate among pneumonia patients with 0-1 MDR risk factor was lower than that for those with ≥2 MDR risk factors (4.5% vs 12.5%, P < .001) (Table 3) . Similarly, the PSI score, CURB-65, and need for ICU admission and mechanical ventilation were significantly lower in pneumonia patients with 0-1 MDR risk factor than in the patients with ≥2 MDR risk factors, respectively: 91 (75-116) vs 119 (98-145) (P < .001); 1 (1-2) vs 2 (1-2) (P < .001): data are presented as median (interquartile range); and 4.3% vs 30.6 % (P < .001) ( Table 3 ).
Therapy
Among all 1089 patients (regardless of following the algorithm), 46 (4.2%) received inappropriate therapy, including 17 (2.6%) with CAP, 7 (2.9%) with HCAP, 14 (10%) with HAP, and 8 (14.5%) with VAP. If a combination of the broadest-spectrum antibiotics for each of the 4 groups, as recommended in the algorithm, had been administered to all patients, 40 (3.7%) would have received inappropriate therapy, including 29 (4.4%) with CAP, 6 (2.5%) with HCAP, 4 (2.9%) with HAP, and 1 (1.8%) with VAP ( Table 3 ). The pathogens not covered by the algorithm are shown in Supplementary Table 3 . Eight hundred ninety-eight patients (82.5%) received empiric therapy recommended by the algorithm and 39 of 898 (4.3%) got inappropriate therapy. The remaining 191 patients (17.5%) did not receive empiric therapy recommended by the algorithm and 7 of 191 (3.7%) got inappropriate therapy. Seventy-four patients (6.8%) received narrower-spectrum antibiotic therapy than the regimen recommended by the algorithm and 7 of them (9.5%) got inappropriate therapy. For this group, the frequency of inappropriate therapy was higher than for the patients who adhered to the algorithm (7/74 [9.5%] vs 39/898 [4.3%], P = .053). One hundred seventeen patients (10.7%) received broader-spectrum therapy than recommended by the algorithm, and none (0/117) got inappropriate therapy (Supplementary Table 4 ).
In those with 0-1 MDR risks and those with ≥2 MDR risks, treatment failure (in 77 pneumonia patients with 0-1 MDR risk (10.2%) and 57 pneumonia patients in ≥2 MDR risks [16.9%] ) was more common than inappropriate therapy (Table 3) .
Multivariate Mortality Analysis
A univariate and multivariate regression analysis of all pneumonia patients appears in Table 5 . In the multivariate analysis, the independent correlates of 30-day mortality were advanced age (≥75 years), hematocrit <30%, malnutrition (albumin <3.0 g/ dL), dehydration (BUN ≥21 mg/dL), inappropriate therapy, chronic liver disease, and hypotension (systolic blood pressure ≤90 mm Hg) ( Table 5) .
Analysis for patients not intubated at the time of pneumonia onset (CAP, HCAP, and HAP) appears in Supplementary  Table 5 . Site of origin of pneumonia and the presence of MDR pathogens were not identified as risk factors for 30-day mortality.
DISCUSSION
We prospectively enrolled 1089 patients with all types of pneumonia and demonstrated the utility of a single algorithm, based on MDR risk factors, and not site of pneumonia acquisition. We found MDR pathogens more often in the high-risk group than in the low-risk group (25.8% vs 5.3%, P < .001). The algorithm was followed in 898 of 1089 patients (82.5%) and, when the recommended therapy was followed, it led to an inappropriate choice in only 4.3% of patients and would have led to inappropriate therapy in only 3.7% of the entire population, if all had used it. In addition, most of the time, when the algorithm was not followed, it was because patients received broader-spectrum therapy than recommended. Thus the unified algorithm not only provided accurate empiric therapy recommendations, but did so without the overuse of antibiotics that occurred when the algorithm was not followed. In addition, we observed a 7% 30-day mortality for all patients (4.5% of the low-risk group, 12.5% of the high-risk group; and 4.7% for CAP, 6.7% for HCAP, 13.6% for HAP, and 18.2% for VAP), lower than in prior reports [3, 10, 17] . Although MDR pathogens were not identified in a multivariate analysis as a risk for 30-day mortality, we did observe a significant correlation with inappropriate therapy and mortality. Furthermore, while the presence of HAP and VAP were mortality risk factors in univariate analysis, there was no significant association in multivariate analysis with the site of pneumonia acquisition and mortality. Instead, patient factors (advanced age [≥75 years], hematocrit <30%, malnutrition [albumin <3.0 g/dL], dehydration [BUN ≥21 mg/dL] and chronic liver disease), hypotension, and inappropriate therapy were identified mortality risk factors.
In this study, the observed bacteriology was similar to prior studies, with S. pneumoniae, Haemophilus influenzae, and atypical pathogens being common in CAP. While some studies have reported that the etiology of HCAP is the same as HAP [9, 10] , others have suggested that the etiology is more similar to CAP [2] [3] [4] [5] [6] . We found that in HCAP the frequency of Compared with pneumonia with 0-1 MDR risks and pneumonia with ≥2 MDR risks.
MDR pathogens was higher in the high-risk HCAP group than in the low-risk group (15.8% vs 5.1%, P = .008; Supplementary Table 2 ), similar to our previous experience [11] . The frequencies of Enterobacteriaceae, S. pneumoniae, S. aureus (MRSA), and P. aeruginosa were high with HAP, and other than the relatively high frequency of S pneumoniae in HAP, the results were almost the same as prior studies [17, 27, 28] . Martin-Loeches et al found that patients with late-onset infection and risks for MDR pathogens had a similar frequency of MDR pathogens as those without risk factors for resistant pathogens [17] . In our study, we considered occurrence ≥5 days after admission to hospital for HAP and VAP as a risk factor for MDR pathogens, along with severe illness. As 72% of HAP patients had a history of treatment with antibacterial drugs, 95% developed pneumonia after 5 days in the hospital, and 92% had poor functional status, we classified 96.4% into the high MDR risk group. Similarly, VAP patients invariably had 2 risk factors (ie, management with a ventilator and decrease in activity), and thus all were severe and classified into the high MDR risk group (group 4), and treatments covering MDR pathogens were recommended.
In the high-risk group, the severity score (PSI score, CURB-65) and the frequency of factors that affect the outcome, such as poor functional status, hypotension, respiratory failure, malnutrition, and dehydration, was high, and since 91.7% had received appropriate initial treatments, it seemed that outcome was determined more by patient comorbidity than by the etiologic pathogen, when the therapy algorithm was followed. In a study by Shindo et al, patients with CAP and HCAP also had patient factors determine outcome [27] .
Recent epidemiologic studies of CAP and HCAP have attempted to prevent excessive administration of antibiotics by assessing the risk factors for resistant pathogens [11] [12] [13] [14] [15] 18] . In a previous study, we applied an algorithm based on the MDR risk factors to 321 HCAP patients and achieved good outcome without overuse of antibiotics [11] . In the current study, we extended this approach to all types of pneumonia patients, and when the algorithm was not followed, broader-spectrum therapy than recommended was given to 117 patients, whereas only 74 received narrower-spectrum therapy than recommended. Use of nonadherent narrow-spectrum therapy led to inappropriate therapy in 9.5% of patients, with the greatest impact on patients with CAP and VAP (Supplementary Table 4 ).
Limitations of this study include its conduct only in Japan; the algorithm needs to be applied in other countries, with different healthcare systems. For example, we used mechanical ventilation and ICU admission to define severe pneumonia, but these modalities may not be offered to terminally ill patients, thus potentially limiting the application of our algorithm. Finally, the algorithm does not include therapy for viral infection, although patients with viral infection and suspected bacterial coinfection were included (Table 4) .
CONCLUSIONS
We have shown that by using an algorithm, based on risk factors for resistant pathogens, and severity of illness, but not site of pneumonia acquisition, we could not only simplify pneumonia treatment, but also could improve the accuracy of empiric therapy, and reduce mortality, while avoiding the overuse of broad-spectrum therapy in some patients. We found that patient factors and use of appropriate initial treatment were more important than the site of pneumonia acquisition to determine outcome. Use of our algorithm has the possibility to eliminate excessive use of antibiotics and simplify pneumonia treatment, while leading to a high rate of appropriate empiric therapy with an associated good outcome. This algorithm should be verified in other clinical settings, and could be supplemented by hospital-specific antibiograms, to optimize antibiotic choice of HAP and VAP. 
